Update _2_0_173H

Clinical Reminders

VA-COVID-19 IMMUNIZATION REMINDER UPDATE H Install Guide

May 2021

Product Development
Office of Information Technology
Department of Veterans Affairs

Table of Contents

Introduction

DESCRIPTION: This update revises the top portion (above the COVID-19 Immunization Actions section) of the VA-SARS-COV-2 IMMUNIZATION and VA-SARS-COV-2 IMMUNIZATION TEMPLATE reminder dialogs. Age range information for each approved vaccine has been added. Branching logic has also been added to display adolescent specific information for the Pfizer vaccine if the patient is 12-17 years old. The update also revises the text in the following four template fields.

IM SARS COV-2 INFO TEXT PRIORITIZATION WARNING

- Update: Essential worker warning removed from dialog.

IM SARS COV-2 INFO TEXT CDC ACIP

- Update: Essential worker warning removed from dialog, COVID-19 vaccines and other vaccines may now be administered without regard to timing, and persons with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as heparin-induced thrombocytopenia, should not receive the Janssen COVID-19 vaccine if it has been ≤90 days since their illness resolved.

IM SARS COV-2 VA SIDE EFFECTS AE REPORTING

- Update: URL for the VA side effects reporting form has been updated.

IM SARS COV-2 INFO TEXT ANAPHYLAXIS

- Update: Persons with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as heparin-induced thrombocytopenia, should not receive the Janssen COVID-19 vaccine if it has been ≤90 days since their illness resolved.

UPDATE_2_0_173H contains 1 Reminder Exchange entry:
UPDATE_2_0_173H VA-COVID-19 IMMUNIZATION REMINDER

REMINDER TERMS

VA-REMINDER UPDATE_2_0_173H
VA-COVID-19 ADOLESCENT AGE RANGE

REMINDER SPONSOR

NATIONAL CENTER FOR HEALTH PROMOTION AND DISEASE PREVENTION (NCP)

TEMPLATE FIELDS

IM SARS COV-2 INFO TEXT CDC ACIP
IM SARS COV-2 INFO TEXT ANAPHYLAXIS
IM SARS COV-2 ADOLESCENT-CHILD APPROVAL TEXT
IM SARS COV-2 INFO TEXT EUA AGES
IM SARS COV-2 VA PRE SCREEN FORM
IM SARS COV-2 CDC VACCINE PHASED IMPLEMENTATION URL

IM SARS COV-2 CDC VACCINE INFO URL
IM SARS COV-2 VHA VACCINE INFO URL
IM SARS COV-2 INFO TEXT OTHER
IM SARS COV-2 INFO TEXT
IM SARS COV-2 PROVIDER EUA FACT URL A1
IM SARS COV-2 PROVIDER EUA FACT URL D2
IM SARS COV-2 PROVIDER EUA FACT URL C2

HEALTH SUMMARY COMPONENT
PCE IMMUNIZATIONS SELECTED
PCE IMMUNIZATIONS SELECT CHRON

HEALTH SUMMARY TYPE
SARS-COV-2 IMMUNIZATION

HEALTH SUMMARY OBJECTS
SARS-COV-2 IMMUNIZATION (TIU)

TIU DOCUMENT DEFINITION
SARS-COV-2 IMMUNIZATION

REMINDER DIALOG
SARS-COV-2 IMMUN UPDATE 173H V2.8

Install Details

This update is being distributed as a web host file. The address for the host file is:
https://vaww.va.gov/reminders/docs/UPDATE_2_0_173H.PRD

The file will be installed using Reminder Exchange, programmer access is not required.

This update can be loaded with users on the system. Installation will take less than 5 minutes

Install Example

To Load the Web Host File. Navigate to Reminder exchange in Vista



At the **Select Action:** prompt, enter **LWH** for Load Web Host File
At the **Input the url for the .prd file:** prompt, type the following web address:
https://REDACTED /UPDATE_2_0_173H.PRD

Search and locate an entry titled **UPDATE_2_0_173H VA-COVID-19 IMMUNIZATION REMINDER.**



At the **Select Action** prompt, enter **IFE** for Install Exchange File Entry
Enter the number that corresponds with your entry **UPDATE_2_0_173H VA-COVID-19 IMMUNIZATION REMINDER.** *(in this example it is entry 163 it will vary by site).* The date of the exchange file should be 05/24/2021.



At the **Select Action** prompt, type **IA** for **Install All Components** and hit enter.

Overwrite the template fields
Overwrite the health summary type

```
 Item   Seq. Dialog Findings                                        Type     Exists
   1     SARS-COV-2 IMMUN UPDATE 173H V2.8                        dialog

   2    5 VA-TEXT SARS-COV-2 IMMUNIZATION HEADER                 element       X
          Finding: *NONE*

   3    6 VA-TEXT SARS-COV-2 IMMUNIZATION HEADER TEMPLATE        element       X
          Finding: *NONE*

   4    10 VAL-SARS-COV-2 VACCINE INFO TEXT GP                     group       X
          Finding: *NONE*
   5    10.3 VAL-SARS-COV-2 VACCINE INFO TEXT GP 1                 group       X
          Finding: *NONE*
   6    10.3.4 VAL-SARS-COV-2 VACCINE INFO TEXT GP EUA             group       X
          Finding: *NONE*
   7    10.3.4.5 VAL-SARS-COV-2 VACCINE INFO TEXT EUA URLS       element       X
+         + Next Screen    - Prev Screen    ?? More Actions
DD    Dialog Details        DT    Dialog Text           IS    Install Selected
DF    Dialog Findings       DU    Dialog Usage          QU    Quit
DS    Dialog Summary        IA    Install All
Select Action: Next Screen// IA
```

At the **Select Action** prompt, type **IA** for **Install All Components** and hit enter. This element is only used to deploy the TIU template fields.

```
 Item   Seq. Dialog Findings                                        Type     Exists
   1     SARS-COV-2 IMMUN UPDATE 173H V2.8                        dialog       X

   2    5 VA-TEXT SARS-COV-2 IMMUNIZATION HEADER                 element       X
          Finding: *NONE*

   3    6 VA-TEXT SARS-COV-2 IMMUNIZATION HEADER TEMPLATE        element       X
          Finding: *NONE*

   4    10 VAL-SARS-COV-2 VACCINE INFO TEXT GP                     group       X
          Finding: *NONE*
   5    10.3 VAL-SARS-COV-2 VACCINE INFO TEXT GP 1                 group       X
          Finding: *NONE*
   6    10.3.4 VAL-SARS-COV-2 VACCINE INFO TEXT GP EUA             group       X
          Finding: *NONE*
   7    10.3.4.5 VAL-SARS-COV-2 VACCINE INFO TEXT EUA URLS       element       X
+         + Next Screen    - Prev Screen    ?? More Actions
DD    Dialog Details        DT    Dialog Text           IS    Install Selected
DF    Dialog Findings       DU    Dialog Usage          QU    Quit
DS    Dialog Summary        IA    Install All
Select Action: Next Screen// Q
```

You will then be returned to this screen. At the **Select Action** prompt, type **Q.**

```
Date Packed: 05/24/2021@08:50:43
Package Version: 2.0P42

Description:

Keywords:

Components:

ROUTINE
      PXRMPDEM                                                          X

TIU TEMPLATE FIELD
   1  IM SARS COV-2 INFO TEXT CDC ACIP                                  X
   2  IM SARS COV-2 INFO TEXT ANAPHYLAXIS                               X
+         + Next Screen   - Prev Screen   ?? More Actions                >>>
IA   Install all Components             IS   Install Selected Component
Select Action: Next Screen// Q
```

You will then be returned to this screen. At the **Select Action** prompt, type **Q.**

Post-Installation

1. **Confirm the following changes in the VA-SARS-COV-2 IMMUNIZATION reminder dialog.**

A. Essential workers warning removed.

IM SARS COV-2 INFO TEXT PRIORITIZATION WARNING before (Only displayed for outpatients):

```
☐ Detailed information on vaccine for COVID-19

   Note: CDC/ACIP has identified essential workers as a priority group for immunization.
    Essential workers are not identified by reminder evaluation. Many essential workers
    who are high priority for immunization may not have this reminder showing as due even
    though they are a priority group for immunization and should be vaccinated.


  No prior COVID-19 immunization
```

IM SARS COV-2 INFO TEXT PRIORITIZATION WARNING after:

```
☐ Detailed information on vaccine for COVID-19



  No prior COVID-19 immunization
```

B. The URL for the VA side effects reporting form has been updated.

IM SARS COV-2 VA SIDE EFFECTS AE REPORTING template field is in each vaccine administration option.



C. COVID-19 Vaccine VHA/CDC Recommendations have been updated.

IM SARS COV-2 INFO TEXT CDC ACIP before (highlighted sections have been edited):

Detailed information on vaccine for COVID-19

COVID-19 Vaccine EUA Fact Sheets and EUA Requirements

COVID-19 Vaccine VHA/CDC Recommendations

VHA Vaccine Policies and Guidance including vaccine prioritization:
VHA - COVID-19 Vaccination Guidance

CDC and ACIP Guidance:
CDC - COVID-19 Vaccination Resources

The mRNA COVID-19 vaccine series consist of two doses administered intramuscularly:
Pfizer-BioNTech (30 µg, 0.3 ml): 3 weeks (21 days) apart
Moderna (100 µg, 0.5 ml): 1 month (28 days) apart

The Janssen adenvovirus vectored vaccine is a single dose vaccine administered intramuscularly. Janssen (0.5 ml) vector-nr, rS-Ad26.

For 2 dose vaccines:
Persons should NOT be scheduled to receive the second dose earlier than recommended. However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid. Doses inadvertently administered earlier than the grace period do not need to be repeated. Recipients may be scheduled for their 2nd dose up to 6 weeks after the first dose to accommodate for scheduling circumstances. Doses administered after 6 weeks do not need to be repeated.

Per ACIP, COVID vaccination should be administered alone and spaced from any other vaccine by 14 days (in either direction). ACIP also recommends that vaccine should not be administered for at least 90 days after receiving monoclonal antibodies or convalescent plasma. However, if this suggested spacing does not occur between vaccines or between vaccine and antibody or plasma treatment, no vaccines need to be repeated.

CDC considers a history of the following to be a contraindication to vaccination with both the Pfizer-BioNTech and Moderna COVID-19 vaccines:

Severe allergic reaction (e.g. anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components
Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG])
Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG)

CDC currently recommends that persons who receive an mRNA vaccine be observed after vaccination for the following time periods:
Persons with a history of anaphylaxis (due to any cause): 30 minutes
All other persons: 15 minutes

Appropriate medical treatment for severe allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of COVID-19 vaccine.

Prioritization:
**NOTE: this clinical reminder cannot idenfity essential workers who are priority and may not show as DUE NOW on patients who are a priority for immunization.

ACIP defines frontline essential workers as the subset of essential workers likely at greatest risk for work-related exposure to SARS-CoV-2, the virus that causes COVID-19, because their work-related duties must be performed onsite and their duties involve being in close proximity (<6 feet) to the public or coworkers.

More information on CDC prioritization and definition of essential workers can be found at the URL below.

CDC - COVID-19 Vaccination Phased Implementation

IM SARS COV-2 INFO TEXT CDC ACIP after:



☑ Detailed information on vaccine for COVID-19

☐ COVID-19 Vaccine EUA Fact Sheets and EUA Requirements

☑ COVID-19 Vaccine VHA/CDC Recommendations

VHA Vaccine Policies and Guidance including vaccine prioritization:
VHA - COVID-19 Vaccination Guidance

CDC and ACIP Guidance:
CDC - COVID-19 Vaccination Resources

The mRNA COVID-19 vaccine series consist of two doses administered intramuscularly:
Pfizer-BioNTech (30 µg, 0.3 ml): 3 weeks (21 days) apart
Moderna (100 µg, 0.5 ml): 1 month (28 days) apart

The Janssen adenvovirus vectored vaccine is a single dose vaccine administered intramuscularly. Janssen (0.5 ml) vector-nr, rS-Ad26.

For 2 dose vaccines:
Persons should NOT be scheduled to receive the second dose earlier than recommended. However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid. Doses inadvertently administered earlier than the grace period do not need to be repeated. Recipients may be scheduled for their 2nd dose up to 6 weeks after the first dose to accommodate for scheduling circumstances. Doses administered after 6 weeks do not need to be repeated.

Per ACIP, vaccine should not be administered for at least 90 days after receiving monoclonal antibodies or convalescent plasma. However, if this suggested spacing does not occur between vaccines or between vaccine and antibody or plasma treatment, no vaccines need to be repeated.

CDC considers a history of the following to be a contraindication to vaccination with both the Pfizer-BioNTech and Moderna COVID-19 vaccines:

Severe allergic reaction (e.g. anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components
Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG])
Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG)

CDC currently recommends that persons who receive an mRNA vaccine be observed after vaccination for the following time periods:
Persons with a history of anaphylaxis (due to any cause): 30 minutes
All other persons: 15 minutes

Appropriate medical treatment for severe allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of COVID-19 vaccine.

Persons with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as heparin-induced thrombocytopenia, should not receive the Janssen COVID-19 vaccine if it has been =90 days since their illness resolved. These persons should be offered an mRNA COVID-19 vaccine.

CDC - COVID-19 Vaccination Phased Implementation

D. Information of precautions related to allergy and anaphylaxis updated.

IM SARS COV-2 INFO TEXT ANAPHYLAXIS before (highlighted section has been edited):

☑ Detailed information on vaccine for COVID-19

☐ COVID-19 Vaccine EUA Fact Sheets and EUA Requirements

☐ COVID-19 Vaccine VHA/CDC Recommendations

☑ Information on precautions related to allergy and anaphylaxis

VHA Pre-Vaccination Form for mRNA COVID-19 Vaccines

CDC - Preparing for the Potential Management of Anaphylaxis

VHA recommends:
Review CDC guidance for recognition and management of anaphylaxis at COVID-19 vaccination sites.

Guidance may change as further information becomes available. As new information emerges, sites should update their own protocols to fit local needs. Sites should utilize their best judgement to:
Communicate with patients on vaccine safety.
Screen for contraindications and precautions before administering COVID-19 vaccines.
Implement postvaccination observation periods.
Recognize signs and symptoms of anaphylaxis.
Respond promptly with treatment.

Document any allergic reaction after vaccine, including anaphylaxis, should be reported as an Adverse Event per local policy and in VA ADERS Program

CDC recommends:
Persons who receive a COVID-19 vaccine be observed after vaccination for the following time periods:
Persons with a history of anaphylaxis (due to any cause): 30 minutes
All other persons: 15 minutes

Appropriate medical treatment for severe allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of COVID-19 vaccine.

A clinical provider with access to the emergency equipment should be immediately available to assess and manage anaphylaxis.

IM SARS COV-2 INFO TEXT ANAPHYLAXIS after:

```
☑ Detailed information on vaccine for COVID-19

   ☐ COVID-19 Vaccine EUA Fact Sheets and EUA Requirements
   ☐ COVID-19 Vaccine VHA/CDC Recommendations
   ☑ Information on precautions related to allergy and anaphylaxis

      VHA Pre-Vaccination Form for mRNA COVID-19 Vaccines
      CDC - Preparing for the Potential Management of Anaphylaxis

      VHA recommends:
       Review CDC guidance for recognition and management of anaphylaxis at COVID-19
          vaccination sites.

       Guidance may change as further information becomes available. As new
        information emerges, sites should update their own protocols to fit
        local needs. Sites should utilize their best judgement to:
          Communicate with patients on vaccine safety.
          Screen for contraindications and precautions before administering COVID-19 vaccines.
          Implement postvaccination observation periods.
          Recognize signs and symptoms of anaphylaxis.
          Respond promptly with treatment.

       Document any allergic reaction after vaccine, including anaphylaxis, should be
          reported as an Adverse Event per local policy and in VA ADERS Program

      CDC recommends:
       Persons who receive a COVID-19 vaccine be observed after vaccination for the
          following time periods:
            Persons with a history of anaphylaxis (due to any cause): 30 minutes
            All other persons: 15 minutes

       Persons with a history of an episode of an immune-mediated syndrome characterized
          by thrombosis and thrombocytopenia, such as heparin-induced thrombocytopenia,
          should not receive the Janssen COVID-19 vaccine if it has been =90 days since
          their illness resolved. These persons should be offered an mRNA COVID-19 vaccine.

       Appropriate medical treatment for severe allergic reactions must be immediately
          available in the event that an acute anaphylactic reaction occurs following
          administration of  COVID-19 vaccine.

      A clinical provider with access to the emergency equipment should be immediately
         available to assess and manage anaphylaxis.
```

E. The age-range information for each approved vaccine displays.

```
COVID-19 Immunization (SARS-CoV-2 Immunization) V2.0
☑ Detailed information on vaccine for COVID-19

   ☐ COVID-19 Vaccine EUA Fact Sheets and EUA Requirements
   ☐ COVID-19 Vaccine VHA/CDC Recommendations
   ☐ Information on precautions related to allergy and anaphylaxis

  No prior COVID-19 immunization

  Vaccine                          Age range                    Approval
    Moderna COVID-19 Vaccine         18 years of age and older   EUA
    Pfizer-BioNTech COVID-19 Vaccine 12 years of age and older   EUA
    Janssen COVID-19 Vaccine         18 years of age and older   EUA
```

F. The following information displays for patients 12-17yo.